Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2R -targeted therapy (daclizumab) in multiple sclerosis

CLICK HERE TO DOWNLOAD THE PDF

 

Publication Date: March 2007 /
Author: Amy Packer / Bibiana Bielekova / Henry McFarland / Magdalena Cerna / Marta Catalfamo / Pierre A. Henkart / Roland Martin / Susan Reichert-Scrivner / Thomas A. Waldmann /
Categories: Drugs / Journal Articles / Specific to MS /

2018-01-17T17:00:33+00:00
MAKE A DONATION